STOCK TITAN

DermTech, Inc. - $DMTK STOCK NEWS

Welcome to our dedicated page for DermTech news (Ticker: $DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DermTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DermTech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.18%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.78%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.78%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.42%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
conferences
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
DermTech, Inc.

Nasdaq:DMTK

DMTK Rankings

DMTK Stock Data

21.79M
33.20M
4.24%
21.26%
9.14%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
SAN DIEGO

About DMTK

dermtech is a molecular diagnostic dermatology company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. dermtech operates a clia (clinical laboratory improvement amendments) licensed laboratory located at the company’s la jolla, ca headquarters. dermtech’s technology allows for the analysis of skin biopsy samples collected non-invasively using an adhesive patch. current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. dermtech’s pigmented lesion assay (pla) provides physicians with a non-invasive option for the biopsy of clinically atypical pigmented lesions using an adhesive patch rather than a scalpel. dermtech provides highly accurate, objective information to the physician to improve patient care and comfort and reduce costs. the pla is used for the detection of melanoma in at